Combined Modality Treatment Including Methotrexate-Based Chemotherapy For Primary CENTRAL Nervous System Lymphoma: A Single Institution Experience
2009

Combined Treatment for Primary Central Nervous System Lymphoma

Sample size: 41 publication 10 minutes Evidence: moderate

Author Information

Author(s): Stefan Hohaus, Luciana Teofili, Mario Balducci, Stefania Manfrida, Angelo Pompucci, Francesco D’Alo’, Giuseppina Massini, Luigi Maria Larocca, Roberto Marra, Sergio Storti

Primary Institution: Università Cattolica del Sacro Cuore

Hypothesis

Does the addition of high-dose cytosine arabinoside (HD-AraC) to high-dose methotrexate (HD-MTX) improve treatment outcomes for primary central nervous system lymphoma (PCNSL)?

Conclusion

The addition of HD-AraC did not improve clinical outcomes in PCNSL and increased treatment-related toxicity.

Supporting Evidence

  • 67% of assessable patients achieved complete remission after treatment.
  • Severe infections occurred in 77% of patients receiving HD-AraC.
  • Median overall survival was 22 months.

Takeaway

Doctors tried adding a new medicine to help patients with brain lymphoma, but it didn't make them better and made them sicker instead.

Methodology

Patients received high-dose methotrexate followed by whole brain radiotherapy, with some receiving additional high-dose cytosine arabinoside.

Potential Biases

Potential bias due to non-randomized treatment allocation.

Limitations

The study is limited by its small sample size and retrospective nature.

Participant Demographics

41 HIV-negative patients, median age 59 years, 21 females and 20 males.

Statistical Information

P-Value

0.5

Confidence Interval

95% C.I., 11–39

Statistical Significance

p=0.5

Digital Object Identifier (DOI)

10.4084/MJHID.2009.020

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication